EUVIMEDEUVIMED entdecken
Crossref

HIPK3 hypomethylation as a potential epigenetic biomarker in rheumatic immune diseases with emphasis on rheumatoid arthritis

Ping Jiang, Yi Shen, Cen Chang, Yiming Shi, Kai Wei, Jianan Zhao, Yu Shan, Yixin Zheng, Fuyu Zhao, Shicheng Guo, Dongyi He

Clinical Rheumatology · 2025

DOI: 10.1007/s10067-024-07158-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Ping Jiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Shanghai Guanghua Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, DNA Methylation, Epigenesis, Genetic, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: National Natural Science Funds of China, Shanghai Municipal Health Commission, Research and development of traditional therapies and preparations for arthropathy and transformation of doctoral innovative talent base.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aimed to explore the potential of HIPK3 DNA methylation as a biomarker for rheumatoid arthritis (RA) by examining its methylation levels in various rheumatic immune diseases and analyzing its correlation with clinical indicators. METHODS: We recruited 368 participants, including patients with RA, ankylosing spondylitis (AS), GOUT, psoriatic arthritis (PSA), sjogren's syndrome (SS), systemic lupus erythematosus (SLE), dermatomyositis (DM), and healthy controls (HC), and MethylTargetTM targeted region methylation sequencing technology was employed to analyze the DNA methylation levels of HIPK3 (cg15692052). We analyzed the HIPK3 methylation levels and correlated them with common clinical indicators. Transcriptome data from the GEO dataset (GSE93272) were also analyzed to assess HIPK3 mRNA expression levels in RA patients. Statistical analyses included Spearman correlation, One-Way ANOVA, Kruskal-Wallis tests, and ROC curve analysis. RESULTS: HIPK3 methylation levels were significantly lower in the RA, SLE, and DM groups compared to the HC group (P < 0.05). RA subgroups based on RF and CCP statuses also showed lower HIPK3 methylation levels compared to the HC group (P < 0.05). Analysis of the GEO dataset revealed significantly elevated HIPK3 mRNA expression in RA patients (P < 0.05). A negative correlation was found between HIPK3 methylation levels and ESR (r = -0.14, P = 7.1e-3), CRP (r = -0.25, P = 4.1e-7), RF (r = -0.18, P = 5.2e-4), and DAS28-CRP (r = -0.12, P = 0.04) in the RA group. ROC analysis indicated that HIPK3 methylation levels had high diagnostic value for RA (AUC = 0.742), SLE (AUC = 0.701), and DM (AUC = 0.948), especially in distinguishing seronegative RA (AUC = 0.612, 0.747, 0.836) and differentiating RA from AS (AUC = 0.788). CONCLUSIONS: The study suggests that HIPK3 hypomethylation in peripheral blood is associated with RA and correlated with inflammatory markers, such as CRP. HIPK3 methylation levels have potential as a novel biomarker for RA diagnosis and predicting inflammation trends, showing particular promise in differentiating RA from other types of arthritis. Key Points • MethylTargetTM targeted region methylation sequencing technology was employed to analyze the DNA methylation levels of HIPK3 (cg15692052). • HIPK3 methylation levels have potential as a novel biomarker for RA diagnosis and predicting inflammation trends.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidDNA MethylationEpigenesis, GeneticProtein Serine-Threonine KinasesRheumatic DiseasesCarrier ProteinsHumansMaleFemaleBiomarkersMiddle AgedAdultCase-Control StudiesROC CurveIntracellular Signaling Peptides and Proteins

Stichwörter der Autor:innen

BiomarkerDNA methylationHomeodomain-interacting protein kinase 3InflammationRheumatoid arthritis

Substanzen

BiomarkersHIPK3 protein, humanProtein Serine-Threonine KinasesCarrier ProteinsIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Department of Rheumatology, Shanghai Guanghua Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Guanghua Clinical Medical College, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Institute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin ER Road, Shanghai, 200025, China.
  • Department of Rheumatology, Shanghai Guanghua Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. dongyihe@medmail.com.cn.
  • Guanghua Clinical Medical College, Shanghai University of Traditional Chinese Medicine, Shanghai, China. dongyihe@medmail.com.cn.

Förderung

  • National Natural Science Funds of China
  • Shanghai Municipal Health Commission
  • Research and development of traditional therapies and preparations for arthropathy and transformation of doctoral innovative talent base
  • Sponsored by Shanghai Sailing Program

Zitieren

APA

Jiang, P., Shen, Y., Chang, C., Shi, Y., Wei, K., Zhao, J., Shan, Y., Zheng, Y., Zhao, F., Guo, S., & He, D. (2025). HIPK3 hypomethylation as a potential epigenetic biomarker in rheumatic immune diseases with emphasis on rheumatoid arthritis. Clinical Rheumatology. https://doi.org/10.1007/s10067-024-07158-1

Vancouver

Jiang P, Shen Y, Chang C, Shi Y, Wei K, Zhao J, et al. HIPK3 hypomethylation as a potential epigenetic biomarker in rheumatic immune diseases with emphasis on rheumatoid arthritis. Clinical Rheumatology. 2025. doi:10.1007/s10067-024-07158-1

BibTeX
@article{Jiang2025,
  author = {Jiang, Ping and Shen, Yi and Chang, Cen and Shi, Yiming and Wei, Kai and Zhao, Jianan and Shan, Yu and Zheng, Yixin and Zhao, Fuyu and Guo, Shicheng and He, Dongyi},
  title = {HIPK3 hypomethylation as a potential epigenetic biomarker in rheumatic immune diseases with emphasis on rheumatoid arthritis},
  journal = {Clinical Rheumatology},
  year = {2025},
  doi = {10.1007/s10067-024-07158-1}
}
Kostenlos starten →